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E-mail address: xunxudr@163.com (X. Xu).Thrombomodulin (TM) is a single-transmembrane glycoprotein receptor for thrombin, which is best
known as a cofactor for thrombin-mediated activation of anticoagulant protein C. C-type lectin-like
domain (CTLD) of TM has distinct coagulation/ﬁbrinolysis-independent anti-inﬂammatory proper-
ties. Here we found anti-inﬂammatory effects of a novel peptide (GC31) from CTLD of TM in endo-
toxin-induced uveitis, which was characterized by a reduction of leukocyte counts, protein
concentration, tumor necrosis factor (TNF)-a and monocyte chemoattractant protein (MCP)-1 levels
in aqueous humor. Through in vitro experiments, we further found that GC31 suppressed TNF-a and
interleukin (IL)-6 expressions in lipopolysaccharide (LPS)-stimulated macrophage-like RAW264.7
cells and interrupted LPS-induced nuclear factor-jB (NF-jB) activation. These data indicate a ben-
eﬁcial role of peptide GC31 in preventing intraocular inﬂammatory response, especially uveitis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Macrophage activation by bacterial toxins such as lipopolysac-
charide (LPS) induces secretion of a number of cytokines and
chemokines, such as tumor necrosis factor (TNF)-a, interleukin
(IL)-6, IL-1b, monocyte chemoattractant protein (MCP)-1 [1,2],
which are key inﬂammatory mediators in many chronic inﬂamma-
tory diseases, including rheumatoid arthritis, multiple sclerosis,
and ocular inﬂammatory diseases [2–4]. Uveitis, an ocular inﬂam-
matory condition, is one of the most common causes of blindness
and accounts for 10–20% of cases of legal blindness per year [5].
Autoimmune diseases and infections are considered as the major
causes of uveitis [6]. Corticosteroids are the most frequently pre-
scribed medications for uveitis [5] and usually used as long-term
therapy for severe uveitis to prevent recurrences. However, its sup-
ply is limited due to potentially serious adverse effects, such as
induction of glaucoma, formation of cataracts, decreased resistance
to infection, and decreased wound healing [7]. Therefore,chemical Societies. Published by E
lysaccharide; EIU, endotoxin
or necrosis factor a; MCP-1,
factor kappaBadditional steroid-sparing agents with less adverse effects are ur-
gently needed.
Endotoxin-induced uveitis (EIU) is a widely accepted animal
model of ocular inﬂammation, which is induced by a systemic
injection of a sublethal dose of LPS [8,9]. It is characterized by
the breakdown of blood–eye barrier and inﬁltration of leukocytes
and protein in the eyes [10]. In this model, LPS may directly acti-
vate the vascular endothelium, macrophages, and other cells by
interaction with toll-like receptor 4 (TLR4) [1] and induce cyto-
kines and other inﬂammatory mediators production, such as
TNF-a, IL-6, IL-1b, and MCP-1 [2,11]. TNF-a and IL-6 have been
reported to be involved in the pathogenesis of LPS-induced uveitis
[12]. MCP-1 has also been reported to be present in the plasma of
patients with active Behçet’s disease [13] and in the aqueous
humor (AqH) of patients with active uveitis [14].
Thrombomodulin (TM) is well known for its natural anticoagu-
lant function and anti-inﬂammatory properties [15]. Human TM
consists of 557 amino acid residues arranged in ﬁve distinct
domains including an N-terminal domain with weak sequence
similarity to the family of C-type lectins, six tandemly repeated
epidermal growth factor (EGF)-like domains, a Ser/Thr-rich region,
a transmembrane domain, and a short cytoplasmic tail [16]. It is
increasingly recognized that the C-type lectin-like domain (CTLD)
of TM plays an important role in cell adhesion and inﬂammationlsevier B.V. All rights reserved.
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properties of CTLD may be that the lectin-like module protects
the vasculature and tissues from pro-inﬂammatory stimuli by
interfering with leukocytes adhesion through suppressing adhe-
sion molecules expression via NF-jB and mitogen-activated pro-
tein kinase (MAPK) signaling pathways, overall dampening the
inﬂammatory response [17]. It is reported that mice lacking the
N-terminal domain of TM have an augmented response to lung in-
jury, myocardial ischemia–reperfusion, endotoxemia, and arthritis
and that administration of recombinant lectin-like domain of TM
signiﬁcantly attenuates the development of arthritis [17,18].
In the present study, we identiﬁed and characterized a novel 31-
amino acid peptide with the sequence of GFQWVTGDNNTSYSR-
WARLDLNGAPLCGPLC (named GC31) from the CTLD of TM. We
assessed the peptide’s anti-inﬂammatory properties in EIU. In addi-
tion, to further elucidate the mechanism of the effect of GC31 on
EIU, we determine the anti-inﬂammatory effects of GC31 using
LPS-induced mouse macrophage-like RAW264.7 cells as the model.2. Materials and methods
2.1. Preparation of peptides
According to the characteristics of CTLD structure of the C-type
lectins superfamily [19], we focused on one conserved amino acid
sequence fromCTLD of TM (GC31: GFQWVTGDNNTSYSRWARLDLN-
GAPLCGPLC, molecular weight: 3412.8 Da) in our study. A control
peptide, named VP30 (VISLLLNGDGGVGRRRLWIGLQLPPGCGDP,
molecular weight: 3129.6 Da), was simultaneously synthesized
from the same domain of TM and used in all the following experi-
ments in vitro and in vivo.
A high-efﬁciency solid-phase peptide synthesis was performed
by ChinaPeptides Co., Ltd. in Shanghai, PR China with an automatic
peptide synthesizer (Symphony; Protein Technologies, Tucson, AZ).
The puriﬁed peptide was characterized by analytical high-
performance liquid chromatography (HPLC; Shimadzu, Kyoto,
Japan) and mass spectrometry (MS, Finnigan TSQ 7000; Thermo,
Waltham, MA) with the purity over 95%. All the synthesized pep-
tides were freeze-dried and stored at 20 C until used.2.2. Animals for EIU induction and treatment
Eight-week-old male Wistar rats (weighing 160–220 g), pro-
cured from Sino-Brithish SIPPR/BK LAB.ANIMAL LTD., CO were used
in this study. They were maintained under a 12-h light/12-h dark
cycle. Food and water were supplied ad libitum. All animal exper-
iments were in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
EIU was induced by a single subcutaneous injection of LPS
(200 lg/100 lL, Escherichia coli, 055:B5, Sigma–Aldrich, St. Louis,
MO, USA) in saline into the right hind footpad. Rats were anesthe-
tized by intraperitoneal injection of 0.15 mL pentobarbital (5.47 g/
100 mL saline). Pupils were dilated by instillation of one drop of
tropicamide 5% and one drop of tetracaine 1% was administered
for local anesthesia prior to intravitreal injection. Intravitreal injec-
tions (10 lL) were performed in both eyes using sterile syringes ﬁt-
ted with 29-gauge needle (Ultra-Fine™; Becton Dickinson AG, USA)
under a surgical microscope, as previously described [20]. Injec-
tions were performed 1 mm behind the limbus, and the needle
was left in the eye for 30 s to prevent the liquid to reﬂux. Rats were
injected intravitreally in both eyes with phosphate-buffered saline
(PBS, pH 7.4), GC31 (2, 10 and 20 lg), VP30 (20 lg), DXM (20 lg,
Sigma–Aldrich, St. Louis, MO) diluted in PBS immediately after
LPS injection. Rats of control group or GC31-alone group wereinjected intravitreally with PBS or 20 lg GC31 and without LPS
injection.
There were 10 rats in each group. Aqueous humor of six rats and
eyeballs of the other four rats were collected when rats were under
deep anesthesia and then they were euthanized by cervical
dislocation.
2.3. Inﬁltrating cells and proteins in aqueous humor
Twenty-four hours after LPS injection, the aqueous humor
(AqH) was collected from the eyes immediately by an anterior
chamber puncture with a 30-gauge needle under a surgical micro-
scope. AqH was collected from both eyes of each animal and
pooled.
For cell counting, the AqH samples were suspended in the
Trypan-blue solution (1:5), and applied to a hemocytometer. The
number of cells per ﬁeld (an equivalent of 0.1 lL) was manually
counted under a light microscope (Olympus Optical Ltd., London,
UK), and the number of cells per microliter was obtained by aver-
aging the results of four ﬁelds from each sample. Total protein con-
centration in AqH was measured with a bicinchoninic acid (BCA)
protein assay reagent kit (Pierce, Rockford IL, USA).
2.4. Levels of TNF-a, MCP-1 and IL-6
The levels of TNF-a andMCP-1 inAqHandconcentrationsof TNF-
a and IL-6 in the culture medium were assessed with a commer-
cially available enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems, Minneapolis, MN, USA), according to the manufac-
turer’s instructions. The ELISA assay was performed in duplicate.
2.5. Histopathological examination
Animals were examined under slit lamp at 24 h after LPS injec-
tion and eyes were then enucleated immediately and ﬁxed in 4%
paraformaldehyde for 48 h at room temperature, after which they
were kept in 70% alcohol at 4 C until they were embedded in par-
afﬁn. Sagittal sections (5 lm) were cut near the optic nerve (eight
eyes of four rats in each group) and stained with hematoxylin and
eosin (H&E). The iris–ciliary body complex, anterior chamber, vit-
reous, and retina were observed under light microscope. Inﬁltrat-
ing leukocytes in the anterior chamber and vitreous cavity were
counted in a masked fashion by an ocular pathologist [11].
2.6. Cell culture
RAW264.7, a murine macrophage-like cell line purchased from
the CBCAS (Cell Bank of the Chinese Academic of Sciences,
Shanghai, China) was maintained in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v)
fetal bovine serum (Biochrom, AG, Germany) and antibiotics
(100 U/mL penicillin and 100 lg/mL streptomycin). The cells were
maintained at 37 C in an atmosphere of 5% CO2.
2.7. Cell viability assay
The cell viability of RAW264.7 cells was assessed using the Cell
Titer 96 AQueous One Solution Cell Proliferation Assay (MTS) kit
(Promega, Madison, WI, USA). Brieﬂy, cells were plated in the
96-well plate and allowed to adhere for 24 h. Then cells were trea-
ted with various concentrations of peptides for 24 h. Cells in the
control group were left untreated. After then 20 lL MTS solution
was added to each well and incubated for another 3 h at 37 C.
Absorbance was detected at 490 nm with a microplate reader
(Bio-Rad; Model 680; USA).
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Total RNA was extracted with Trizol reagent (Invitrogen),
according to the manufacturer0s instructions. The ﬂuorescence
quantitative RT-PCR was performed on the Rotor-Gene 3000
(Corbett Research, Australia) instrument with a One-Step SYBR
PrimeScript RT-PCR kit (TaKaRa Bio Inc., Japan) according to the pro-
tocol. Speciﬁc sense and antisense primers used were as follows:
TNF-a, sense: 50-GACGTGGAACTGGCAGAAGAG-30, anti-sense: 50-
TTGGTGGTTTGTGAGTGTGAG-30; IL-6, sense: 50-CTGCAAGA-
GACTTCCATCCAGTT-30, anti-sense: 50-GAAGTAGGGAAGGCCGTGG-
30; GAPDH, sense: 50-CCAAGGAGTAAGAAACC-30; anti-sense: 50-
GCAGCGAACTTTATTGA-30. GAPDH was chosen as a housekeeping
gene where indicated.
2.9. Immunoﬂuorescence staining for NF-jB
RAW264.7 cells were pretreated with GC31 or VP30 (10 lM) for
30 min, and then stimulated with 100 ng/mL LPS for 1 h. After
incubation, cells were washed with Tris-buffered saline, ﬁxed in
cold methanol/acetone (1:1) for 20 min and permeabilized with
0.1% Triton X-100 for 10 min at room temperature. Cells were incu-
bated with NF-jB p65 antibody (1:50, Cell Signaling Technology,
Beverly, MA) in a humid chamber overnight at 4 C. After incubated
with Alexa555-conjugated secondary IgG antibody (1:500; Invitro-
gen) for 45 min, the coverslips were mounted in medium contain-
ing 4,6-diamino-2-phenylindole (DAPI) (Dako Cytomation) onto
the glass slides. Slides were visualized and photographed under a
confocal ﬂuorescence microscope (LSM 510, Carl Zeiss, Gottingen,Fig. 1. Effect of GC31 peptide on LPS-induced protein concentration (A), cell counts (B), T
was collected in rats treated with PBS, GC31, VP30 or DXM alone or combined simultan
were measured using ELISA method. Each value represents the mean ± S.D. of six rats. ⁄Germany). The same exposure was used for photographing all
samples.
2.10. Cytoplasmic and nuclear protein extracts and Western blotting
After cells were rapidly harvested using a cell scraper, nuclear
and cytoplasmic extracts were prepared on ice with ProteoJET cyto-
plasmic and nuclear protein extraction kit (Fermentas Life Science,
Opelstrasse, Germany). Protein concentration was measured by
the Bradford method. Cell homogenates (30–50 lg of protein) were
separated by 10% SDS–PAGE and electro-transferred to polyvinyli-
dene diﬂuoride (PVDF) membranes. After blocking with 5% bovine
serum albumin (BSA), the membrane was incubated overnight
4 C with the target antibody. Each membrane was further incu-
batedwith horseradish peroxidase (HRP)-conjugated goat anti-rab-
bit IgG (1;1000, R&D Systems, Inc.), respectively. LaminA/C (1:1000,
Epitomics, Inc., California, USA) was chosen as a nuclear housekeep-
ing protein in the nuclear extract. The bands were visualized using
the ECL system detection system (Pierce, Rockford, IL, USA), and
the band density was determined by Image J software (NIH, USA).
2.11. Statistical analysis
All the experiments were repeated at least three times. The
results were expressed as mean ± standard deviation (S.D.) and
analysed using one-way analysis of variance (ANOVA) followed
by Bonferroni’s post hoc test using SPSS 16.0 software for multiple
comparisons of mean values. p < 0.05 was considered statistically
signiﬁcant.NF-a (C), and MCP-1 concentration (D) in the aqueous humor. The aqueous humor
eously with LPS (200 lg) challenge for 24 h. The levels of TNF-a (C) and MCP-1 (D)
p < 0.05 and ⁄⁄p < 0.01 versus the LPS group. ##p < 0.01 versus the DXM group.
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3.1. Effect of GC31 on cellular inﬁltration and protein concentration in
aqueous humor
Twenty-four hours after LPS injection, the protein concentration
in AqH of rats increased to 22.09 ± 0.49 mg/mL (n = 6) and GC31
administration signiﬁcantly decreased protein concentrations in a
dose-dependent manner (Fig. 1A). The group treated with 20 lg/
eye DXM exhibited a bit stronger inhibitory ability than 20 lg/eye
GC31 group (GC31: 12.48 ± 1.35 mg/mL; DXM: 10.31 ± 0.53 mg/
mL, Fig. 1A). The level of protein concentration detectable from
theGC31-alone groupwas 5.49 ± 0.57 mg/mL and showedno differ-
ence with the control group. Likewise, the number of leukocytes in
the groups treated with GC31 or DXMwas signiﬁcantly diminishedFig. 2. Histolopathologic features of inﬂammatory cells inﬁltration in ocular tissues 24
alone (B) showed no inﬂammation in the anterior chamber and posterior vitreous cavity
rats (C) and 20 lg VP30 treated rats (D). A signiﬁcant attenuation of inﬂammation was ob
Hematoxylin and eosin staining; original magniﬁcation 100. (G) Effect of GC31, VP30 o
Mean ± S.D. (n = 8 eyes). ⁄⁄p < 0.01 versus the LPS group. #p < 0.05 versus the DXM grouthan that in the LPS group (Fig. 1B). No inﬁltrating cells were de-
tected in AqH of the control group and GC31-alone group. However,
compared with LPS-alone group, treatment with VP30 (20 lg/eye)
or GC31 (2 lg/eye) combinedwith LPS injection resulted in no obvi-
ous reduction in the cell counts and protein concentration (Fig. 1A
and B).
3.2. Levels of TNF-a and MCP-1 in aqueous humor
Secretion of TNF-a and MCP-1 in the AqHwas remarkable in the
LPS group (TNF-a: 460.5 ± 94.96 pg/mL; MCP-1: 4168 ± 191.6 pg/
mL). Treatment with GC31 signiﬁcantly reduced TNF-a and MCP-
1 production, compared with the LPS group (in 10 lg and 20 lg
GC31 group, p < 0.01, Fig. 1 C and D). The effect of 20 lg GC31 on
TNF-a level was almost the same as that for DXM grouph after LPS injection. Rats without LPS injection (A) or with GC31 (20 lg) injection
. Severe inﬂammatory cells inﬁltration was observed in LPS-alone (200 lg) injected
served in rats treated with 20 lg GC31 (E) or 20 lg DXM (F) and LPS simultaneously.
r DXM at indicated concentrations on leukocytes inﬁltration in histological sections.
p.
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eye) showed no inhibitory effects on the TNF-a and MCP-1 concen-
trations (Fig. 1 C and D).
3.3. Histopathologic ﬁndings
Histological examination showed that severe cellular inﬁltra-
tion was observed in the anterior chamber, iris-ciliary bodies,
and posterior vitreous (particularly around the optic nerve head).
In the LPS group, 82 ± 13 inﬂammatory cells per histological sec-
tion were detected (n = 8, Fig. 2C), while inﬂammatory cells in
the GC31 or DXM treated groups were signiﬁcantly decreased
(Fig. 2 E and F). But treatment with VP30 (20 lg) or GC31 (2 lg)
did not induce any decreased grading (Fig. 2 D and G). No inﬂam-
mation was observed histopathologically in rats treated with PBS
or GC31 (20 lg) alone (Fig. 2 A and B).
3.4. GC31 suppresses LPS-induced expression of IL-6 and TNF-a in
RAW264.7 cells
The peptides did not decrease the cell viability of RAW264.7
cells when these cells were incubated with GC31 (0.1 lM, 1 lM,
and 10 lM) or VP30 (10 lM) for 24 h (data not shown).
TNF-a and IL-6 are known as inﬂammatory cytokines which are
correlated with LPS stimulation [2,12]. To assess the effect of GC31
on LPS induced pro-inﬂammatory cytokines up-regulation,
RAW264.7 cells were pretreated with 0.1–10 lM GC31 for 30 minFig. 3. Effects of GC31 on LPS-induced TNF-a and IL-6 production in RAW264.7 ce
simultaneously combined with LPS (100 ng/mL). (A, B) The amounts of TNF-a and IL-6 in
kits. (C, D) The mRNA levels of TNF-a and IL-6 were assessed by RT-PCR analysis 6 h af
represent means ± S.D. of triplicate measurements. ⁄⁄p < 0.01 versus the LPS group.and incubated for 24 h with LPS (100 ng/mL). We observed that
LPS remarkably increased levels of TNF-a and IL-6 in RAW264.7
cells, whereas GC31 signiﬁcantly reduced TNF-a and IL-6 produc-
tions in a dose-dependent fashion (Fig. 3 A and B). GC31 (0.1 lM)
and VP30 (10 lM) did not inﬂuence TNF-a and IL-6 protein level
compare to the LPS group.
We then performed RT-PCR to analyze the effects of GC31 on
LPS-induced TNF-a and IL-6 mRNA levels. As shown in Fig. 3 C
and D, LPS (100 ng/mL) treatment signiﬁcantly elevated TNF-a
and IL-6 mRNA expression, which was suppressed by GC31. How-
ever, VP30 (10 lM) did not demonstrate any inhibitory effect on
TNF-a and IL-6 productions. These data indicated that GC31 might
inhibit the production of TNF-a and IL-6 at the gene transcription
and translation levels in LPS-activated RAW264.7 cells.
3.5. Effects of GC31 on NF-jB activation in LPS-stimulated RAW 264.7
cells
To further characterize the mechanism underlying the effects of
GC31, the activation and translocation of NF-jB were examined.
Firstly, we chose GC31 10 lM to perform immune-ﬂuorescence
staining of NF-jB p65. Nuclear staining was evident after LPS stim-
ulation, indicating that NF-jB had been activated and translocated
to the nucleus (Fig. 4A). In PBS-treated and GC31-treated cells,
cytoplasmic staining with nuclear sparing was evident, whereas
VP30 group had the nuclei stained obviously. Next, we tested the
expression of nuclear NF-jB p65 following 1 h after LPS treatmentlls. The cells were treated with GC31 (0.1 lM, 1 lM, 10 lM) or VP30 (10 lM)
the culture medium 24 h after LPS stimulation were determined using ELISA assay
ter LPS stimulation. GAPDH mRNA was measured as the internal control. The data
Fig. 4. Effects of GC31 on NF-jB activity in LPS-activated RAW264.7 cells. (A) Cells were pre-treated with 10 lM GC31 or VP30 for 30 min and then stimulated with 100 ng/
mL LPS for 1 h. The cells were subjected to an immunoﬂuorescent staining method with anti-NF-jBp65 antibody. (Red: NF-jB p65; Blue: nuclear.) (B) Cells were pre-
incubated with GC31 or VP30 for 30 min and then with 100 ng/mL LPS for 1 h. Nuclear proteins were analyzed by western blot analysis using antibody against NF-jB p65.
Lamin A/C was used as the internal control. (C) The band density was determined by Image J software and the relative level was calculated as the ratio of NF-kB p65 to Lamin
A/C protein expression. The results represent means ± S.D. of three independent experiments. ⁄⁄p < 0.01 versus the LPS group.
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and 10 lM signiﬁcantly inhibited NF-jB p65 protein translocation
compared with the LPS alone group (Fig. 4 B and C). The result sug-
gested that GC31 suppressed LPS-induced activation of NF-jB in
the nuclear fraction in a dose-dependent fashion.
4. Discussion
In view of many side effects of traditional treatments and
repeated occurrences of intraocular inﬂammation, uveitis remains
a challenging ﬁeld to most ophthalmologists. Additional immuno-
suppressive drugs including T-cell inhibitors, anti-metabolites,
alkylating agents and new immunomodulatory agents that target
speciﬁc inﬂammatory cytokines such as TNF-a are also associated
with many adverse effects, such as nephrotoxicity [21], malig-
nancy, multiple sclerosis [22] and high medical cost are concerned.
Moreover, in certain ocular tissues, tight junctions reduce the pas-
sage of drugs from the blood to the eye, thus limiting the bioavail-
ability of immunosuppressors in ocular tissues. As a result, short
peptides become ideal alternatives for treating uveitis, owing to
their sufﬁcient penetration capability, potentially low immunoge-
nicity, and less toxicity [23].
As mentioned before, the CTLD of TM plays a distinct role in
anti-inﬂammation by interfering with leukocyte adhesion, comple-
ment activation and cytokine generation [17,18,24]. In this study,
we synthesized a novel peptide, GC31, from a conserved sequenceof TM to investigate their potential anti-inﬂammatory activity
in vitro and in vivo.
It has been well documented that many inﬂammatory media-
tors, such as TNF-a, IL-6, MCP-1, and macrophage inﬂammatory
protein (MIP)-2, have been involved in rabbits, rats, and mice with
EIU, which can induce increased protein concentration in the
aqueous humor [2,11,12,25]. In the present study, we found that
GC31 signiﬁcantly inhibited LPS-induced TNF-a and MCP-1 secre-
tion in AqH and level of IL-6 and TNF-a in RAW264.7 cell medium,
which demonstrated the anti-inﬂammatory effects of GC31 on pre-
venting the increase of pro-inﬂammatory factors stimulated by
LPS. TNF-a is a pivotal inﬂammatory mediator by inducing the syn-
thesis of other cytokines, such as MCP-1, IL-8, intercelluar adhesion
molecule (ICAM)-1, enhancing inﬂammatory cells adherence to the
endothelium, and promoting inﬂammatory responses [2,25–27].
MCP-1 is uniquely essential for monocyte recruitment during
inﬂammation and the number of ocular inﬂammatory cells was
signiﬁcantly reduced in MCP-1/mice of EIU [11,14,27]. Therefore
it indicates that GC31 reduction of leukocyte inﬁltration in the AqH
and vitreous cavity is caused, at least in part, by its inhibition of
MCP-1 and TNF-a expression. In addition, Conway [17] showed
that the lectin-like domain of TM could interfere with leukocyte
adhesion to ECs by ICAM-1 – dependent pathway. ICAM-1 is upreg-
ulated and expressed on vascular endothelial cells of the iris and
the ciliary body shortly after LPS injection [28]. Therefore, another
possible mechanism for the suppression of inﬂammatory cells exu-
H. Jin et al. / FEBS Letters 585 (2011) 3457–3464 3463dation by peptide GC31 could be due to inhibition of LPS induced
ICAM-1 production.
NF-jB, a ubiquitously expressed family of transcription factors
of various genes [29], is known to play a crucial role in macrophage
activation and regulation of inﬂammatory cytokine genes in re-
sponse to TLR4 signals [30]. TNF-a is activated through NF-jB, also
activates NF-jB, thus promoting its own secretion and generating a
positive loop that ampliﬁes the cytokine cascade and the inﬂam-
matory response [29]. In the in vitro study, we found that GC31
could signiﬁcantly suppress NF-jB nucleus translocation in
LPS-stimulated RAW264.7 cells, which raised a possibility that
the positive loop between TNF-a and NF-jB might be interfered
by GC31. Based on some studies which showed that TNF-a-in-
duced ICAM-1 and MCP-1 expression required NF-jB activity
[25,26] and NF-jB activation in EIU tissue specimens was largely
detected [31], we concluded that the anti-inﬂammatory properties
of peptide GC31 were performed by blocking LPS-activated NF-jB
translocation, inhibiting pro-inﬂammatory mediators expression
and then dampening the EIU.
The CTLD of C-type lectin superfamily has a double-loop struc-
ture and the long loop region which lies within the domain is
involved in Ca2+-dependent carbohydrate binding [19]. The loca-
tion of GC31 in CTLD of TM corresponds to the long loop region.
GC31 structure analysis by the Expert Protein Analysis System
(ExPASy) proteomics server (http://heliquest.ipmc.cnrs.fr/) shows
that some part of the sequence (TSYSRWARLDLNGAPLCGPLC) is
amphipathic and retains cationic and hydrophobic faces. This
structure is thought to be important for interaction with a nega-
tively charged amphipathic LPS [32]. Meanwhile, Shi CS [24] dem-
onstrated that CTLD of TM inhibited LPS-induced inﬂammatory
mediator production via binding to LPS and speciﬁcally interacting
with Lewis Y, a tetrasaccharide expressed on the surface of patho-
gens. Accordingly, this novel peptide GC31 rather than VP30 might
have a possible site for interaction between CLTD and LPS antigen
and may play an anti-inﬂammatory role in LPS-induced
inﬂammation.
We performed gross examination for all experimental animals,
and no corneal edema, cataract, vitreous hemorrhages, or retinal
detachment was found in all groups 24 h after EIU induction.
And light microscopy demonstrated that the iris-ciliay body and
retinal morphology in GC31-alone group had no distinguishable
ﬁndings from the control group; no evident signs of inﬂammation
or immune reaction were found in GC31-alone group. This infor-
mation primarily indicated that its effective concentration (10
and 20 lg) in the study had no obvious tissue toxicity and immu-
nogenicity. Although its biologic activity is not as strong as that of
DXM, the latter has many impressive side effects described above.
Some limitations of the present study need to be considered.
First, the study focused on parameters of inﬂammatory response,
but not data concerning the exact mechanism of action of GC31.
We can ascertain that the peptide exerts its effects through the
inhibition of inﬂammatory mediators production mediated by
the inhibition of NF-jB. However, the interaction between GC31
and LPS deserves further studies. Second, the used model (EIU)
has certainly been useful in elucidating a variety of mediators that
are activated in the eye, and testing a wide variety of potential
pharmacologic inhibitors [8,20,31,32], but there are various
immune abnormalities including genetic elements, infectious
agents, and autoimmune components implicated in uveitis. The ef-
fect of peptide GC31 in the LPS-induced uveitis was demonstrated
in the current study, however its ability to counteract ocular
inﬂammation induced by other causes needs to be elucidated in
the future researches by other animal models (experimental auto-
immune uveitis for instance).
In summary, the present study demonstrated that in vivo
administration of GC31 reduced intraocular inﬂammatoryresponse in EIU by inhibition of protein and inﬂammatory cells
inﬁltration and pro-inﬂammatory cytokines production. Moreover,
GC31 inhibited the activation of NF-jB and suppressed the tran-
scription and production of TNF-a and IL-6 cytokines in LPS-stim-
ulated RAW264.7 cells. These ﬁndings suggest that the novel
peptide GC31, a sequence of TM lectin-like domain, may be ad-
dressed as a promising therapeutic agent in LPS induced intraocu-
lar inﬂammation.
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